DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for prostatitis — screening already-approved drugs against its 37-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleProstatitis maps to a 37-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for prostatitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphodiesterase 4D (PDE4D) — PDE4D is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet difluoromethoxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5WH6 · 1.6 Å · ligand 1-[4-(difluoromethoxy)-3-{[(3S)-oxolan-3-yl]oxy}phenyl]-3-methylbutan-1-one (AKJ). Experimental structure, not a prediction.
What the evidence adds up to
Prostate inflammation, or prostatitis, is a pathological change in prostate tissue that can be categorised by clinical and laboratory findings. A 2017 review notes that research is focusing on the immunological events within the prostate, and that similar serous and cellular reactions may occur regardless of the cause of inflammation. These reactions may interact with other prostate pathologies such as benign prostate hyperplasia or prostate cancer. The review suggests potential treatments could come from understanding the inflammatory mechanism, but does not present any clinical trial data.
A 1947 paper on head and neck surgery describes a type of prostatitis in detail and discusses its aetiology without advancing any theory of causation. It states that further careful and comprehensive investigations with controls will be needed before the problem is solved and a more efficient treatment is developed. A 2009 Russian-language review of chronic prostatitis treatment concludes that therapy should be complex, addressing all parts of the aetiology and pathogenesis, and that an individual approach to each patient improves effectiveness. It provides no specific drug efficacy data.
A 2019 study tested electric stimulation hyperthermia treatment (ESHT) in a rat model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). In lipopolysaccharide-induced RWPE-2 cells and in rats with prostatitis induced by 17β-estradiol and dihydrotestosterone, ESHT induced suppressor of cytokine signaling 3 (SOCS3) expression and promoted HSP70. It attenuated inflammation through decreased expression of toll-like receptor 4 (TLR4), nuclear factor kappa B, and subsequent inflammatory cytokines, and also inhibited apoptosis and released growth factor. The study reports that ESHT improved CP/CPPS and reversed pathologic changes in rats, but no human data are provided.
No randomised controlled trials in humans with prostatitis are presented in these abstracts. What is missing is any clinical trial testing a specific drug in patients, any human survival or response rate data, and any evidence that the SOCS3-TLR4 pathway findings in rats translate to men. The field lacks adequately funded, controlled human studies with clear patient stratification.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Urological Science · 2017 · 16 citations · open access
Prostate inflammation: A brief review
AbstractProstate inflammation, also known as prostatitis, is defined as a pathological inflammatory change in prostate tissue. Based on clinical and laboratory findings, it can be categorized into different groups. Recent prostate inflammation researches are focusing on the immunological events within prostate. Despite the etiology of inflammation, prostate may go through similar serous and cellular reactions to defend itself from all types of danger signals. These reactions may have further interaction with different prostate pathologies, such as benign prostate hyperplasia or prostate cancer. Potential treatment options may be derived from understanding of inflammatory mechanism.
AbstractThe type of prostatitis encountered is described in detail, and its aetiology is discussed. No theory of its causation is advanced. Further careful and more comprehensive investiga- tions, with the use of controls, will have to be undertaken before the problem is finally solved and a more efficient and rapid form of treatment of the condition is evolved.
The World Journal of Men s Health · 2019 · 11 citations · open access
Electric Stimulation Hyperthermia Relieves Inflammation <i>via</i> the Suppressor of Cytokine Signaling 3-Toll Like Receptor 4 Pathway in a Prostatitis Rat Model
AbstractPURPOSE: Chronic prostatitis (CP), including chronic pelvic pain syndrome (CPPS), is the most commonly encountered manifestation of prostatitis. The aim of this study was to evaluate the effect of electric stimulation hyperthermia treatment (ESHT) on CP/CPPS and to explore the underlying mechanism. MATERIALS AND METHODS: RWPE-2 cells with lipopolysaccharide-induced inflammation and a prostatitis rat model induced by 17β-estradiol and dihydrotestosterone underwent sham, electric stimulation, or ESHT treatment. Four weeks later, cells, supernatants, and rat prostates were collected for analysis using immunohistochemistry, Western blots, and enzyme-linked immunosorbent assays. RESULTS: . ESHT significantly induced suppressor of cytokine signaling 3 (SOCS3) expression and subsequently promoted HSP70. It attenuated inflammation through decreased expression of toll-like receptor 4 (TLR4), nuclear factor kappa B, and subsequent inflammatory cytokines. ESHT also inhibited apoptosis and released growth factor in tissue affected by prostatitis. CONCLUSIONS: ESHT improved CP/CPPS and reversed pathologic changes of prostatitis by inhibiting the SOCS3-TLR4 pathway.
Современные методы лечения хронического простатита (обзор литературы)
AbstractThe review demonstrates a comparative evaluation of the current methods of chronic prostatitis treatment. The common views on existing methods of therapy of such patients are discussed. Was shown that the treatment of patients with chronic prostatitis should be complex and needs to keep in mind the action on all parts of the etiology and pathogenesis chains. The individual approach to each patient allows to construct a more deep and careful specific treatment scheme, improving, therefore, the effectiveness and quality of the results.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
